Ophthalmologica
Original Paper
Ischemic Optic Neuropathy in a Female Carrier with Fabry's DiseaseAbe H.a · Sakai T.a · Sawaguchi S.a · Hasegawa S.a · Takagi M.a · Yoshizawa T.a · Usui T.a · Horikawa Y.baDepartment of Ophthalmology, Niigata University School of Medicine, and bNeurology Clinic, Shinrakuen Hospital, Niigata, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: March 28, 1992
Accepted: April 13, 1992
Published online: April 01, 2010
Issue release date: 1992
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Abstract
We report ocular findings of a patient with anterior ischemic optic neuropathy (AION) and cilioretinal artery occlusion in a female carrier of Fabry’s disease. Fluorescein angiography revealed delayed filling of the upper and temporal part of peripapillary choroidal vessels and capillaries of the right optic disk and late filling of the cilioretinal artery. CT scanning was performed several times in early stages and demonstrated thickening of the intraorbital optic nerve due to ischemic edema. About 5 months later, the fellow eye showed optic disk edema, an early sign of AION, and was treated by systemic corticosteroid and urokinase whereby AION did not progress.
© 1992 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: March 28, 1992
Accepted: April 13, 1992
Published online: April 01, 2010
Issue release date: 1992
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)
For additional information: https://www.karger.com/OPH
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission